Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
43.9M
-
Shares change
-
+745K
-
Total reported value, excl. options
-
$119M
-
Value change
-
+$1.78M
-
Put/Call ratio
-
0.83
-
Number of buys
-
48
-
Number of sells
-
-46
-
Price
-
$2.71
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2022
128 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2022.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.9M shares
of 193M outstanding shares and own 22.69% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.54M shares), VANGUARD GROUP INC (5.2M shares), Hudson Bay Capital Management LP (4.67M shares), MILLENNIUM MANAGEMENT LLC (4.16M shares), Two Seas Capital LP (3.5M shares), Assenagon Asset Management S.A. (2.12M shares), STATE STREET CORP (1.96M shares), BROOKFIELD ASSET MANAGEMENT INC. (1.92M shares), FourWorld Capital Management LLC (1.8M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.79M shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.